#South Korea #Samsung Biologics #Incheon #ExellenS #Plant 4

Samsung Biologics Reports Strong Financial Results for Q3 2025

Incheon, South Korea – On October 28, 2025, Samsung Biologics (KRX: 207940.KS), a preeminent contract development and manufacturing organization (CDMO), revealed robust financial performance for the third quarter of the fiscal year 2025. This period marked a significant operational achievement with a consolidated revenue reaching KRW 1,660.2 billion and an operating profit of KRW 728.8 billion.

According to CEO John Rim, this solid performance stems from their commitment to operational excellence and strategic execution, which has been crucial for fostering global partnerships and reliability. "Our third quarter results reflect the solid foundation we have built through operational excellence and disciplined execution," Rim stated. He emphasized the company's ongoing goal of ensuring that every product manufactured contributes positively to patient health on a global scale.

Financial Highlights

For the third quarter of 2025, Samsung Biologics showcased:

• - Consolidated Revenue: KRW 1,660.2 billion (up from KRW 1,187.1 billion YoY)
• - Operating Profit: KRW 728.8 billion (up from KRW 338.6 billion YoY)
• - EBITDA: KRW 907.8 billion (up from KRW 495.4 billion YoY)

In standalone results, the revenue stood at KRW 1,257.5 billion, attributed to stable operations across all its production facilities and expanded project execution capabilities. The company remains confident in its annual revenue growth guidance due to persistent client demand and optimized capacity use.

Business Developments

In addition to the solid financials, Samsung Biologics secured new contracts with global pharmaceutical partners, pushing cumulative contract volumes to over USD 20 billion since its inception. This expansion further cements the trust clients have in the company’s capabilities across various modalities.

As part of their future-focused strategy, the planned spin-off aimed at separating the CDMO business from its subsidiary is on schedule to conclude by November 2025. This strategic move is anticipated to enhance both entities' focus, allowing Samsung Biologics to cater better to client needs and bolster long-term competitiveness as a dedicated, pure-play CDMO.

Moreover, Samsung Biologics introduced ExellenS™, its optimized manufacturing framework designed to enhance operational efficiency and excellence. By leveraging standardized designs, equipment, and processes, the ExellenS™ framework usher in improvements in flexibility, speed-to-market, and rapid approvals, which are critical in today's fast-paced industry.

Commitment to Sustainability

In an era of growing environmental awareness, Samsung Biologics has strengthened its ESG (Environmental, Social, and Governance) initiatives. The company has established a Product Carbon Footprint (PCF) measurement system aimed at evaluating and managing emissions throughout its operations and supply chain. As an active member of the Sustainable Markets Initiative’s Health Systems Task Force, Samsung Biologics is dedicated to achieving carbon neutrality aligned with enhanced climate goals and is working closely with suppliers to adopt shared sustainable practices.

As the company heads toward the end of the fiscal year, Samsung Biologics is positioned well to meet its annual growth targets, based on consistent client demands and efficient operational execution. The emphasis remains on delivering innovative, reliable services within a framework of sustainability, thus reinforcing Samsung Biologics' standing as a trustworthy partner in the global healthcare landscape.

About Samsung Biologics

Samsung Biologics is a distinguished contract development and manufacturing organization (CDMO) presented with a comprehensive service portfolio that spans from late-stage discovery to commercial manufacturing. The company holds an impressive combined biomanufacturing capacity of 784,000 liters across five state-of-the-art plants, utilizing advanced technologies to advance various therapeutic modalities.

The ExellenS™ framework ensures plant equivalency and speed for uninterrupted manufacturing, while commercial offices in Korea, the U.S., and Japan facilitate global client support. Samsung Biologics is committed to maximizing operational performance and quality excellence, ensuring safe, high-quality biomedicines are delivered on time.

For more information, visit Samsung Biologics.